Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9194830 | 0.77 | — | — | |
| SCHEMBL7526938 | 0.77 | CSNK1A1 (0.31) | — | |
| SCHEMBL3158628 | 0.77 | DPP4 (0.50) | — | |
| SCHEMBL10617985 | 0.77 | PNP (0.48) | ALDH1A1ALOX15 | |
| SCHEMBL29495248 | 0.77 | NUDT1 (0.39) | — | |
| SCHEMBL14440041 | 0.73 | — | — | |
| SCHEMBL7228428 | 0.69 | ADORA3 (0.53) | ALDH1A1 | |
| SCHEMBL6016629 | 0.68 | EGLN1 (0.43) | ALDH1A1TSHR | |
| SCHEMBL3277524 | 0.65 | ALDH1A1 (0.30) | ALDH1A1ALOX15TSHR | |
| SCHEMBL37384 | 0.64 | DPP4 (0.66) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030191086-A1 | Substituted nitrogen heterocyclic derivatives and pharmaceutical use thereof | USTAV EXPERIMENTALNI BOTANIKY AV CR | 2003-10-09 | — | — | US | claimed |
| EP-1147108-B1 | SUBSTITUTED NITROGEN HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL USE THEREOF | USTAV EX BOTAN AKADEMIE VED CE (CZ) | 2003-08-13 | — | — | EP | claimed |
| EP-1147108-A1 | SUBSTITUTED NITROGEN HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL USE THEREOF | Ustav Experimentalni Botaniky Akademie ved Ceské Republiky (CZ) | 2001-10-24 | — | — | EP | claimed |
| WO-2000043394-A1 | SUBSTITUTED NITROGEN HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL USE THEREOF | ÚSTAV EXPERIMENTÁLNÍ BOTANIKY AV CR (CZ) | 2000-07-27 | — | — | WO | claimed |
| US-4134792-A | Specific binding assay with an enzyme modulator as a labeling substance | MILES LABORATORIES, INC. (US) | 1979-01-16 | — | — | US | claimed |
| WO-2023092781-A1 | PREPARATION METHOD FOR REVERSE OSMOSIS MEMBRANE, AND REVERSE OSMOSIS MEMBRANE PREPARED THEREBY | 沃顿科技股份有限公司 | 2023-06-01 | — | — | WO | disclosed |
| CN-116159449-A | Method for preparing reverse osmosis membrane and reverse osmosis membrane prepared by same | 沃顿科技股份有限公司 | 2023-05-26 | — | — | CN | disclosed |
| US-20230104311-A1 | NOVEL 6-SUBSTITUTED 7-DEAZAPURINES AND CORRESPONDING NUCLEOSIDES AS MEDICAMENTS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-04-06 | — | — | US | disclosed |
| EP-4106763-A1 | NOVEL 6-SUBSTITUTED 7-DEAZAPURINES AND CORRESPONDING NUCLEOSIDES AS MEDICAMENTS | Katholieke Universiteit Leuven KU Leuven Research & Development (BE) | 2022-12-28 | — | — | EP | disclosed |
| CN-115515593-A | Novel 6-substituted 7-deazapurines and corresponding nucleosides as medicaments | 勒芬天主教大学 | 2022-12-23 | — | — | CN | disclosed |
| US-7524847-B2 | Fused 1,3-dihydro-imidazole ring compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-04-28 | — | — | US | disclosed |
| US-20070197533-A1 | Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2007-08-23 | — | — | US | disclosed |
| US-5756253-A | PROCESSING OF DIFFUSION TRANSFER PHOTOGRAPHIC FILM UNITS IN PRESENCE OF HYPOXANTHINE AND INOSINE | POLAROID CORPORATION (US) | 1998-05-26 | — | — | US | disclosed |
| US-4724200-A | CRYSTAL STRUCTURE | EASTMAN KODAK COMPANY (US) | 1988-02-09 | — | — | US | disclosed |
| EP-0134928-B1 | Imidazo[1,5-a]pyrimidine derivatives and process for their preparation | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1988-02-03 | — | — | EP | disclosed |
| US-4680255-A | Emulsions and photographic elements containing silver halide grains having tetrahexahedral crystal faces | EASTMAN KODAK COMPANY (US) | 1987-07-14 | — | — | US | disclosed |
| US-4680256-A | Emulsions and photographic elements containing silver halide grains having trisoctahedra crystal faces | EASTMAN KODAK COMPANY (US) | 1987-07-14 | — | — | US | disclosed |
| US-4680254-A | Emulsions and photographic elements containing silver halide grains having hexoctamedral crystal faces | EASTMAN KODAK COMPANY (US) | 1987-07-14 | — | — | US | disclosed |
| US-4134792-A | Specific binding assay with an enzyme modulator as a labeling substance | MILES LABORATORIES, INC. (US) | 1979-01-16 | — | — | US | disclosed |
| US-4001031-A | CHLORINATED ORGANIC FUEL CONVERTS POTASSIUM OXIDE TO POTASSIUM CHLORIDE | CHEM-TROL POLLUTION SERVICES, INC. (US) | 1977-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191086-A1 | Substituted nitrogen heterocyclic derivatives and pharmaceutical use thereof | CDK4, CDK5, CCNI | ALDH1A1 4084/4885ALOX15 3898/4885TSHR 3907/4885 |
| US-20070197533-A1 | Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds | DDC, DPP3, AMPD3 | ALDH1A1 2233/4885ALOX15 2890/4885TSHR 4325/4885 |
| US-20230104311-A1 | NOVEL 6-SUBSTITUTED 7-DEAZAPURINES AND CORRESPONDING NUCLEOSIDES AS MEDICAMENTS | ADA, ADAR, TPMT | ALDH1A1 444/4885ALOX15 3059/4885TSHR 3631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.